4D Pharma PLC ADR (LBPS)

9.21
+0.03(+0.33%)
  • Volume:
    7,817
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    9.18 - 9.36

LBPS Overview

Prev. Close
9.18
Day's Range
9.18-9.36
Revenue
-
Open
9.22
52 wk Range
8.97-18.38
EPS
-0.36
Volume
7,817
Market Cap
1.66B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
-
P/E Ratio
-
Beta
-
1-Year Change
-13.76%
Shares Outstanding
180,300,967
Next Earnings Date
Dec 01, 2021
What is your sentiment on 4D Pharma PLC ADR?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellSell
Technical IndicatorsSellBuyStrong BuyStrong SellStrong Sell
SummarySellNeutralNeutralStrong SellStrong Sell

4D Pharma PLC ADR Company Profile

4D Pharma PLC ADR Company Profile

Employees
92

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn’s disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Read More
  • $LOAC 4D Pharma has huge potential
    1
    • bought 30 at 10dollars
      1
      • This is going to the moon 🚀🚀🚀
        2
        • This is going to the moon 🚀🚀🚀
          1
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.